Idiopathic nephrotic syndrome newly affects 1–3 per 100,000 children per year.
Approximately 85% of cases show complete remission of proteinuria following …

In 2013, we published a set of clinical practice recommendations for the treatment of Alport
syndrome in this journal. We recommended delaying the initiation of angiotensin-converting …

Background The association between early changes in albuminuria and kidney and
cardiovascular events is primarily based on trials of renin-angiotensin system blockade. It is …

Children with Alport syndrome develop renal failure early in life. Since the safety and
efficacy of preemptive nephroprotective therapy are uncertain we conducted a randomized …

Importance Kidney disease is common in infants admitted to the neonatal intensive care unit
(NICU). Despite the risk of chronic kidney disease (CKD) in infants discharged from the …

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world among
patients undergoing renal biopsy. Approximately 30% of patients with IgAN develop end …

Background Early reduction in albuminuria with an SGLT2 (sodium‐glucose cotransporter 2)
inhibitor may be a positive indicator of long‐term cardiovascular and renal benefits. We …

Children born with a solitary functioning kidney (SFK) have an increased risk of
hypertension and kidney disease from early in adulthood. In response to a reduction in …

Background Therapeutic hypothermia (TH) is a well-established neuroprotective therapy
applied in (near) term asphyxiated infants. However, little is known regarding the effects of …

Background Angiotensin-converting enzyme inhibitors (ACEis) have evolved as a first-line
therapy for delaying end-stage renal failure (ESRF) in Alport syndrome (AS). The present …